190 related articles for article (PubMed ID: 27013366)
1. Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer.
Li D; O'Reilly EM
Surg Oncol Clin N Am; 2016 Apr; 25(2):311-26. PubMed ID: 27013366
[TBL] [Abstract][Full Text] [Related]
2. Novel directions in neoadjuvant therapy for pancreas adenocarcinoma.
Yang A; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):585-601. PubMed ID: 25686370
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
[TBL] [Abstract][Full Text] [Related]
4. [Chemoradiation for pancreatic adenocarcinoma].
Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy for pancreas adenocarcinoma.
O'Reilly EM
J Surg Oncol; 2013 Jan; 107(1):78-85. PubMed ID: 22886586
[TBL] [Abstract][Full Text] [Related]
6. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
Maurel J; Sánchez-Cabús S; Laquente B; Gaba L; Visa L; Fabregat J; Povés I; Roselló S; Díaz-Beveridge R; Martín-Richard M; Rodriguez J; Sabater L; Conill C; Cambray M; Reig A; Ayuso JR; Valls C; Ferrández A; Bombí JA; Ginés A; García-Albéniz X; Fernández-Cruz L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):935-943. PubMed ID: 30225601
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Christians KK; Tsai S; Mahmoud A; Ritch P; Thomas JP; Wiebe L; Kelly T; Erickson B; Wang H; Evans DB; George B
Oncologist; 2014 Mar; 19(3):266-74. PubMed ID: 24569947
[TBL] [Abstract][Full Text] [Related]
9. Current status of adjuvant therapy for pancreatic cancer.
Katz MH; Fleming JB; Lee JE; Pisters PW
Oncologist; 2010; 15(11):1205-13. PubMed ID: 21045189
[TBL] [Abstract][Full Text] [Related]
10. The recent past and future of adjuvant therapy for pancreatic cancer.
Yeo CJ
Ann Surg Oncol; 2003 Jun; 10(5):488-9. PubMed ID: 12794012
[No Abstract] [Full Text] [Related]
11. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Motoi F; Satoi S; Honda G; Wada K; Shinchi H; Matsumoto I; Sho M; Tsuchida A; Unno M;
J Gastroenterol; 2019 Feb; 54(2):194-203. PubMed ID: 30182219
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
Bao PQ; Ramanathan RK; Krasinkas A; Bahary N; Lembersky BC; Bartlett DL; Hughes SJ; Lee KK; Moser AJ; Zeh HJ
Ann Surg Oncol; 2011 Apr; 18(4):1122-9. PubMed ID: 21104328
[TBL] [Abstract][Full Text] [Related]
13. Treatment of early-stage pancreatic cancer.
Castellanos EH; Cardin DB; Berlin JD
Oncology (Williston Park); 2011 Feb; 25(2):182-9. PubMed ID: 21456390
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy, chemoradiotherapy or observation after complete resection of pancreatic adenocarcinoma?].
Lluís F
Gastroenterol Hepatol; 2009 Feb; 32(2):120-1. PubMed ID: 19231687
[No Abstract] [Full Text] [Related]
15. Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.
Sohal DPS
Chin Clin Oncol; 2017 Jun; 6(3):26. PubMed ID: 28705003
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant and adjuvant strategies for pancreatic cancer.
Ghaneh P; Smith R; Tudor-Smith C; Raraty M; Neoptolemos JP
Eur J Surg Oncol; 2008 Mar; 34(3):297-305. PubMed ID: 17936564
[TBL] [Abstract][Full Text] [Related]
17. Chemoradiation protocols offer only incremental gains for pancreatic cancer patients.
Bankhead C
J Natl Cancer Inst; 2002 Nov; 94(22):1670-2. PubMed ID: 12441320
[No Abstract] [Full Text] [Related]
18. [Adjuvant and additive therapy for cancer of the pancreas].
Neoptolemos JP; Raraty MG; Ghaneh P; Hickey H; Stocken DD; Dunn JA; Friess H; Büchler MW
Chirurg; 2003 Mar; 74(3):191-201. PubMed ID: 12647075
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemoradiation for pancreatic cancer: few good data, much debate.
Twombly R
J Natl Cancer Inst; 2008 Dec; 100(23):1670-1. PubMed ID: 19033566
[No Abstract] [Full Text] [Related]
20. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Hammel P; Huguet F; van Laethem JL; Goldstein D; Glimelius B; Artru P; Borbath I; Bouché O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C;
JAMA; 2016 May; 315(17):1844-53. PubMed ID: 27139057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
